Sanofi (SNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 10:02AM EDT. Market open.
| Previous Close | 49.46 |
| Open | 49.48 |
| Bid | 49.36 x 200 |
| Ask | 49.47 x 200 |
| Day's Range | 49.34 - 49.60 |
| 52 Week Range | 42.63 - 55.93 |
| Volume | |
| Avg. Volume | 2,124,574 |
| Market Cap | 124.396B |
| Beta (5Y Monthly) | 0.45 |
| PE Ratio (TTM) | 25.74 |
| EPS (TTM) | 1.92 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 2.04 (4.12%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 58.92 |
- Thomson Reuters StreetEvents
Q1 2024 Kymera Therapeutics Inc Earnings Call
Q1 2024 Kymera Therapeutics Inc Earnings Call
ZacksRegeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Regeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
GlobeNewswirePress Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially reduced RSV lower respiratory tract disease and hospitalizations in infants during the 2023-2024 RSV season, versus no intervention1-6Results add to the consistent high efficacy of Beyfortus against medically attended RSV lower respiratory tract disease, shown in the pivotal clinical studies and the outcomes from HARMONIE, a p
© 2024 Yahoo. All rights reserved.